| . | SPVI (n = 42) . |
|---|---|
| Mean follow-up, years (range) | 5 (SD 1.7, range 3–8) |
| FFAs without AAD (n, %) | 29 (69%) |
| FFAs with AAD (n, %) | 35 (83%) |
| FFA with additional transcatheter ablation, no AAD | 31 (74%) |
| FFA with additional transcatheter ablation and AAD | 36 (86%) |
| Freedom from anti arrhythmic drugs | 32 (76%) |
| Freedom from oral anticoagulants | 39 (93%) |
| Mortality at follow-up (n, %) | 0 (0%) |
| Late stroke (>30 day), (n, %) | 0 (0%) |
| . | SPVI (n = 42) . |
|---|---|
| Mean follow-up, years (range) | 5 (SD 1.7, range 3–8) |
| FFAs without AAD (n, %) | 29 (69%) |
| FFAs with AAD (n, %) | 35 (83%) |
| FFA with additional transcatheter ablation, no AAD | 31 (74%) |
| FFA with additional transcatheter ablation and AAD | 36 (86%) |
| Freedom from anti arrhythmic drugs | 32 (76%) |
| Freedom from oral anticoagulants | 39 (93%) |
| Mortality at follow-up (n, %) | 0 (0%) |
| Late stroke (>30 day), (n, %) | 0 (0%) |
FFA, freedom from atrial arrhythmias.
| . | SPVI (n = 42) . |
|---|---|
| Mean follow-up, years (range) | 5 (SD 1.7, range 3–8) |
| FFAs without AAD (n, %) | 29 (69%) |
| FFAs with AAD (n, %) | 35 (83%) |
| FFA with additional transcatheter ablation, no AAD | 31 (74%) |
| FFA with additional transcatheter ablation and AAD | 36 (86%) |
| Freedom from anti arrhythmic drugs | 32 (76%) |
| Freedom from oral anticoagulants | 39 (93%) |
| Mortality at follow-up (n, %) | 0 (0%) |
| Late stroke (>30 day), (n, %) | 0 (0%) |
| . | SPVI (n = 42) . |
|---|---|
| Mean follow-up, years (range) | 5 (SD 1.7, range 3–8) |
| FFAs without AAD (n, %) | 29 (69%) |
| FFAs with AAD (n, %) | 35 (83%) |
| FFA with additional transcatheter ablation, no AAD | 31 (74%) |
| FFA with additional transcatheter ablation and AAD | 36 (86%) |
| Freedom from anti arrhythmic drugs | 32 (76%) |
| Freedom from oral anticoagulants | 39 (93%) |
| Mortality at follow-up (n, %) | 0 (0%) |
| Late stroke (>30 day), (n, %) | 0 (0%) |
FFA, freedom from atrial arrhythmias.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
